Management of Injection Site Reactions
For mild to moderate injection site reactions, apply cool compresses to the affected area, consider topical corticosteroids for inflammation, and use oral antihistamines for pruritus. 1
Assessment and Classification
- Evaluate the severity of the reaction by assessing the extent of erythema, presence of pain, swelling, and any systemic symptoms 1
- Injection site reactions can be classified as:
- Determine if the reaction is localized or if there are signs of systemic involvement that would indicate anaphylaxis 2
Management Algorithm Based on Severity
For Mild Local Reactions
- Apply cool compresses to reduce inflammation and provide comfort 1
- Consider topical corticosteroids for localized erythema and inflammation 1
- Administer oral antihistamines if pruritus is present 1
- Monitor the site for resolution, which typically occurs within a few days 1, 3
For Moderate-to-Severe Local Reactions
- For extensive local reactions without systemic symptoms:
- Monitor the site daily for changes in appearance 1
- If symptoms worsen rather than improve over 24-48 hours, reassessment is recommended 1
For Severe Reactions with Systemic Symptoms (Anaphylaxis)
- Stop medication administration immediately 2
- Maintain intravenous access and assess ABCs (Airway, Breathing, Circulation) 2
- Administer epinephrine 0.2-0.5 mg (1 mg/mL) IM, repeating every 5-15 minutes as needed 2
- Provide fluid resuscitation with normal saline 2
- Administer H1/H2 antagonists: diphenhydramine 50 mg IV plus ranitidine 50 mg IV 2
- Consider corticosteroids at a dose equivalent to 1-2 mg/kg of IV methylprednisolone every 6 hours 2
- Monitor vital signs until resolution and observe for 24 hours after severe reactions 2
Prevention Strategies for Future Injections
- Ensure proper injection technique 1
- Consider rotation of injection sites if multiple injections are needed 1
- For medications with known risk of injection site reactions:
- Patient education about proper self-injection techniques can significantly reduce the incidence of reactions 3
Special Considerations
- Injection site reactions are not typically correlated with drug efficacy or development of antidrug antibodies 3
- Misunderstanding the pathophysiology of injection site reactions (most are not allergic or immunogenic) might result in unnecessary discontinuation of treatment 3
- For biological agents, ISRs are reported in 0.5-40% of patients but are generally mild and rarely require discontinuation of therapy 3, 5
- In rare cases, delayed injection site reactions can occur days or even weeks after administration and may require systemic therapy 4